Status:
RECRUITING
Study on the Optimization of the Diagnostic Process for Chronic Rhinitis Using Nasal Allergen Provocation Test
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Chronic Rhinitis
Eligibility:
All Genders
18-75 years
Brief Summary
Chronic rhinitis (CR) is one of the most prevalent global diseases, with studies estimating that up to 30% of the worldwide population is affected. In China, the prevalence of chronic rhinitis ranges ...
Eligibility Criteria
Inclusion
- AR patients:
- Aged 18-75 years;
- patients who visited the Department of Otorhinolaryngology,the First Affiliated Hospital of Nanjing Medical Uncversity and were willing to undergo nasal provocation test; 3.Ptients who are willing to provide specimens for free to promote the study of the diagnostic efficacy of nasal provocation.
- Healthy volunteers:
- Aged 18-75 years;
- Did not have any nasal symptoms and tested negative for allergens
Exclusion
- Acute rhinosinusitis or acute exacerbation of chronic rhinosinusitis; active phase or symptom exacerbation of allergic diseases (e.g., allergic rhinitis, asthma).
- History of severe allergic reactions (e.g., anaphylaxis).
- Severe chronic obstructive pulmonary disease (COPD) or severe cardiopulmonary diseases contraindicating epinephrine use.
- Active phase of other severe systemic diseases (e.g., malignancies, autoimmune diseases).
- Within 1 week post-vaccination.
- Pregnancy, lactation, or preconception period.
- Inability to comply with study procedures (particularly children under 5 years old).
- Recent nasal surgery (within 2 months), nasal deformities (e.g., choanal atresia, severe nasal septum deviation/perforation), dry/atrophic rhinitis, severe nasal obstruction (e.g., hypertrophic rhinitis, rhinitis medicamentosa), or uncontrolled epistaxis.
- Current use of anti-allergy medications, including:Intranasal agents: corticosteroids, antihistamines, decongestants, anticholinergics, sodium cromoglicate;Systemic agents: oral antihistamines, oral/injectable corticosteroids.
Key Trial Info
Start Date :
March 24 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06999044
Start Date
March 24 2025
End Date
December 1 2028
Last Update
May 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210000